Department of Health appoints Teva and Sanofi veteran as commercial head

pharmafile | July 27, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Department of Health, Sanofi, Teva, biotech, drugs, government, healthcare, pharma, pharmaceuticals 

The UK Government has announced a new appointment within the Department of Health: Steve Oldfield, a former veteran of Teva and Sanofi, has been selected as the department’s new Chief Commercial Officer.  

Oldfield’s new role makes him the most senior commercial manager in the department. Reporting to Permanent Secretary Chris Wormald, he will “lead the development of commercial capability and sharing of commercial best practice across the wider health family to the benefit of the whole system”, the department said. This will include driving better delivery and improved cost performance, while also holding responsibility for the department’s key role in the Government’s overall commercial function.

On the news of Oldfield’s appointment, Wormald remarked: “I am delighted that, working with GCF, we have been able to secure Steve Oldfield as our new CCO. We face a number of commercial challenges across the health family, not least putting in place the next generation of the medicines pricing scheme, but we see huge opportunities for better delivery for patients and better value for money for the taxpayers from improved commercial skills and experience.”

Oldfield’s career in the industry spans more than 25 years, previously serving as UK Managing Director for both Sanofi and Teva. He currently holds the position of Chief Operating Officer for PGT, a joint venture from Proctor & Gamble and Teva in the consumer health sphere. He has also served on the Board of the ABPI and has maintained a presence in industry-government initiatives, co-chairing committees dedicated to improving access to new medicines.

“I’m pleased to hear the announcement by the Department of Health today that Steve Oldfield will take up the new role of Chief Commercial Officer, effective October 2017,” commented the ABPI’s Chief Executive, Mike Thompson. “Steve is well known to the ABPI.  His extensive experience in senior pharmaceutical roles as UK Managing Director for Sanofi and Teva will provide the DH with valuable industry expertise. I’m confident that this appointment will also positively impact our ability to have open and transparent negotiations with Government and find win-win solutions in which everyone can have confidence.”

Oldfield himself noted: “I am delighted to be joining the Department of Health, especially at such an exciting time. Demands on the health system have never been greater, and I hope to be able to bring my previous commercial experience to bear on the activities of the department. In particular, I look forward to working collaboratively across the department, the NHS and the life sciences to find new ways of working for the benefit of patients and the health economy.”

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content